Ecnoglutide
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Ecnoglutide
Ecnoglutide is a once-weekly GLP-1 receptor agonist developed by Sciwind Biosciences, with Phase III trials ongoing in China and international markets. It has shown efficacy and tolerability comparable to semaglutide in head-to-head Phase II comparisons. It represents the expanding pipeline of GLP-1 agents that may increase global access and competitive pricing in the obesity treatment landscape.
Science
Mechanism of Action
Binds and activates GLP-1 receptors with high affinity and a structural design conferring extended half-life for once-weekly dosing, producing appetite suppression, enhanced insulin secretion, and slowed gastric emptying through canonical GLP-1 signaling pathways.
Dosing
Typical Protocol
Weekly subcutaneous injection; Phase III doses titrated from 2–10 mg weekly.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Ecnoglutide is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.